^
Association details:
| Biomarker: | SMARCA4 mutation |
|---|---|
| Cancer: | Gastric Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1425P - Immune microenvironment and genomic alterations interpret heterogeneous response to immunotherapy in EBV-associated gastric carcinoma
Published date:
09/13/2021
Excerpt:
All the EBVaGC patients with SMARCA4 mutation attained PR (P=0.045) and had numeral longer PFS and OS than their wild-type counterpart (P =0.399; P =0.484)...SMARCA4 and 13q12.12 deletion were potential biomarkers of EBVaGC patients regarding to ICB.
